Rimadyl 50 mg, 20 tablets
Rimadyl 50 mg Tablet and 100 mg Chewable Tablet for Dogs (20 tablets)
Clinical particulars
Target species
Dogs
Indications for use
Reduction of inflammation and pain caused by musculo-skeletal disorders and degenerative joint disease.
As a follow-up to parenteral analgesia in the management of post-operative pain.
Contraindications
Do not use in pregnant and lactating bitches.
Do not use in dogs aged less than 4 months in the absence of specific data.
Do not use in cats.
Do not use in dogs, suffering from cardiac, hepatic or renal disease, when there is a possibility of gastrointestinal ulceration or bleeding or where there is evidence of blood dyscrasia.
Do not use in case of hypersensitivity to the active substance, to other NSAIDs and to any of the excipients.
Special precautions for use
Use in dogs less than 6 weeks of age, or in aged dogs, may involve additional risk. If such a use cannot be avoided, dogs may require a reduced dosage and careful clinical management.
Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity.
Concurrent administration of potential nephrotoxic drugs should be avoided.
NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated.
As with other NSAIDs, photodermatitis during treatment with carprofen has been observed in laboratory animals and in humans. These skin reactions have never been observed in dogs.
Do not administer other NSAIDs concurrently or within 24 hours of each other. Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs, which can lead to toxic effects.